SI2895174T1 - Predzdravila amino kinazolin kinaznega inhibitorja - Google Patents
Predzdravila amino kinazolin kinaznega inhibitorja Download PDFInfo
- Publication number
- SI2895174T1 SI2895174T1 SI201330964T SI201330964T SI2895174T1 SI 2895174 T1 SI2895174 T1 SI 2895174T1 SI 201330964 T SI201330964 T SI 201330964T SI 201330964 T SI201330964 T SI 201330964T SI 2895174 T1 SI2895174 T1 SI 2895174T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutically acceptable
- hydrate
- compound
- acceptable salt
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Claims (11)
- Predzdravila amino kinazolin kinaznega inhibitorja Patentni zahtevki1. Spojina, ki je 2-((4-(benzo[c/]tiazoI-5-ilamino)-6-(terc.-butilsulfonil)kinazolin-7-il)oksi)etil dihidrogen fosfat s formulo:ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh.
- 2. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po zahtevku 1, ki je 2-((4-(benzo[i/]tiazol-5-ilamino)-6-(im:.-butilsulfonil)kinazolin-7-il)oksi)etil dihidrogenfosfat.
- 3. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po zahtevku 1, ki je 2-((4-(benzo[ifltiazol-5-ilamino)-6-(/erc.-butilsulfonil)kinazolin-7-il)oksi)etil dinatrijev fosfat.
- 4. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po zahtevku 1, ki je kalcij (I) 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc.-butilsulfonil)kinazolin-7-il)oksi)etil hidrogenfosfat trihidrat.
- 5. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po zahtevku 1, kije 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc.-butilsulfonil)kinazolin-7-il)oksi)etil dihidrogenfosfat hidroklorid monohidrat.
- 6. Farmacevtski sestavek, ki obsega spojino ali njeno farmacevtsko sprejemljivo sol ali hidrat le-teh po katerem koli od zahtevkov 1-5 in farmacevtsko sprejemljiv ekscipient.
- 7. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po katerem koli od zahtevkov 1-5 za uporabo v terapiji.
- 8. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po katerem koli od zahtevkov 1-5 za uporabo pri zdravljenju bolezni ali motnje, izbrane izmed uveitisa, sindroma mrzlice, povezanega z encimom, ki pretvaija interlevkin-1, dermatitisa, akutne poškodbe pljuč, diabetesa mellitusa tipa 2, artritisa, revmatoidnega artritisa, ulcerativnega kolitisa, Crohnove bolezni, vnetne črevesne bolezni z zgodnjim začetkom, ekstraintestinalne vnetne črevesne bolezni, preprečevanja ishemične reperfuzijske poškodbe pri transplantaciji trdnega organa, nealkoholnega steatohepatitisa, alkoholnega steatohepatitisa, avtoimunskega hepatitisa, astme, bolezni presadka proti gostitelju, sistemskega eritematoznega lupusa, multiple skleroze, sarkoidoze, Blau-sindroma/sarkoidoze z zgodnjim začetkom, Wegenerjeve granulomatoze in intersticijske pljučne bolezni.
- 9. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh za uporabo po zahtevku 8, kjer je bolezen ali motnja izbrana izmed Crohnove bolezni, ulcerativnega kolitisa in Blau-sindroma.
- 10. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po zahtevku 4, ki je kristaliničen kalcij (I) 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc.-butilsulfonil)kinazolin-7-il)oksi)etil hidrogenfosfat trihidrat, ki ima PXRD s sl. 1.
- 11. Spojina ali njena farmacevtsko sprejemljiva sol ali hidrat le-teh po zahtevku 5, ki je kristaliničen 2-((4-(benzo[d]tiazol-5-ilamino)-6-(terc.-butilsulfonil)kinazolin-7-il)oksi)etil dihidrogenfosfat hidroklorid monohidrat, ki ima PXRD s sl. 2.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261700422P | 2012-09-13 | 2012-09-13 | |
US201361767387P | 2013-02-21 | 2013-02-21 | |
EP13837571.2A EP2895174B1 (en) | 2012-09-13 | 2013-09-13 | Prodrugs of amino quinazoline kinase inhibitor |
PCT/US2013/059619 WO2014043446A1 (en) | 2012-09-13 | 2013-09-13 | Prodrugs of amino quinazoline kinase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2895174T1 true SI2895174T1 (sl) | 2018-04-30 |
Family
ID=50278703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201330964T SI2895174T1 (sl) | 2012-09-13 | 2013-09-13 | Predzdravila amino kinazolin kinaznega inhibitorja |
Country Status (33)
Country | Link |
---|---|
US (3) | US9586953B2 (sl) |
EP (2) | EP2895174B1 (sl) |
JP (1) | JP6246813B2 (sl) |
KR (1) | KR102101527B1 (sl) |
CN (1) | CN104619327B (sl) |
AR (1) | AR092529A1 (sl) |
AU (1) | AU2013315396B2 (sl) |
BR (1) | BR112015005694A2 (sl) |
CA (1) | CA2886467C (sl) |
CL (1) | CL2015000614A1 (sl) |
CR (1) | CR20150132A (sl) |
CY (1) | CY1120236T1 (sl) |
DK (1) | DK2895174T3 (sl) |
DO (1) | DOP2015000060A (sl) |
EA (1) | EA028146B1 (sl) |
ES (1) | ES2663237T3 (sl) |
HK (2) | HK1212223A1 (sl) |
HR (1) | HRP20180411T1 (sl) |
HU (1) | HUE036347T2 (sl) |
IL (1) | IL237263B (sl) |
LT (1) | LT2895174T (sl) |
ME (1) | ME02985B (sl) |
MX (1) | MX371356B (sl) |
NZ (1) | NZ628452A (sl) |
PE (1) | PE20150635A1 (sl) |
PH (1) | PH12015500363A1 (sl) |
PL (1) | PL2895174T3 (sl) |
PT (1) | PT2895174T (sl) |
RS (1) | RS57144B1 (sl) |
SG (1) | SG11201501139RA (sl) |
SI (1) | SI2895174T1 (sl) |
TW (1) | TWI592417B (sl) |
WO (1) | WO2014043446A1 (sl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012225735B2 (en) | 2011-03-04 | 2016-03-10 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
ES2654100T3 (es) | 2013-02-21 | 2018-02-12 | Glaxosmithkline Intellectual Property Development Limited | Quinazolinas como inhibidores de quinasa |
GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
MX2018011831A (es) | 2016-04-04 | 2019-02-13 | Chemocentryx Inc | Antagonistas solubles de receptor de c5aa(c5ar). |
PE20190979A1 (es) | 2016-09-15 | 2019-07-09 | Boehringer Ingelheim Int | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 |
WO2020043122A1 (zh) * | 2018-08-28 | 2020-03-05 | 南京明德新药研发有限公司 | 作为rip2激酶抑制剂的喹唑啉类衍生物 |
WO2020094613A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nod2 inhibitors for the treatment of hereditary periodic fevers |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4916135A (en) | 1989-05-08 | 1990-04-10 | Hoechst Roussel Pharmaceuticals Inc. | N-heteroaryl-4-quinolinamines |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
WO1998005647A1 (en) | 1996-08-01 | 1998-02-12 | Dow Agrosciences Llc | Quinolinium derivatives having fungicidal activity |
JP2001500890A (ja) | 1996-09-25 | 2001-01-23 | ゼネカ リミテッド | Vegfのような成長因子の作用を阻害するキノリン誘導体 |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
WO2000020402A1 (en) | 1998-10-01 | 2000-04-13 | Astrazeneca Ab | Chemical compounds |
GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
WO2001021596A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
WO2001055116A2 (en) | 2000-01-28 | 2001-08-02 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
AU2001276536B2 (en) | 2000-08-09 | 2007-01-04 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
GB0104422D0 (en) | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
DE60211317T2 (de) | 2001-03-23 | 2007-04-12 | Bayer Corp. | Rho-kinase inhibitoren |
PT1370552E (pt) | 2001-03-23 | 2007-04-30 | Bayer Pharmaceuticals Corp | Inibidores de rho-quinase |
SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
SI1463506T1 (sl) | 2001-12-24 | 2010-01-29 | Astrazeneca Ab | Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
US20040122161A1 (en) | 2002-12-21 | 2004-06-24 | Paul Charles W. | Hot melt adhesive based on acrylic block copolymers |
SI1578755T1 (sl) | 2002-12-24 | 2007-12-31 | Astrazeneca Ab | Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
CA2527017A1 (en) | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors |
WO2005003100A2 (en) | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
GB0321620D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
WO2005026150A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
DK2392564T3 (da) | 2003-09-26 | 2014-01-13 | Exelixis Inc | c-Met-modulatorer og anvendelsesfremgangsmåder |
BRPI0418102A (pt) | 2003-12-23 | 2007-04-27 | Pfizer | derivados de quinolina |
CA2560286A1 (en) | 2004-03-23 | 2005-09-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
WO2005115145A2 (en) | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
EP2295054A1 (en) | 2004-05-27 | 2011-03-16 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
CA2569404A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
FR2873695A1 (fr) | 2004-07-30 | 2006-02-03 | Palumed Sa | Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien |
EP1833830B1 (de) | 2004-12-22 | 2009-10-14 | Bayer Schering Pharma Aktiengesellschaft | Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
ITMI20052008A1 (it) | 2005-10-21 | 2007-04-22 | Ctg Pharma S R L | Nuovi antimalarici derivati della 4-aminochinolina |
FR2902100A1 (fr) | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
US7511063B2 (en) | 2006-08-16 | 2009-03-31 | Schering Corporation | High affinity quinoline-based kinase ligands |
JP2008063278A (ja) | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | 1−ピリジン−4−イル−インドール類の製造方法 |
US7977347B2 (en) | 2006-09-11 | 2011-07-12 | Curis, Inc. | Quinazoline based EGFR inhibitors |
SG174772A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
WO2008033749A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Quinazoline based egfr inhibitors containing a zinc binding moiety |
TW200829555A (en) | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
WO2008119771A2 (en) | 2007-03-30 | 2008-10-09 | Clanotech Ab | Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors |
MX2009011089A (es) | 2007-04-23 | 2009-10-30 | Sanofi Aventis | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
US11103497B2 (en) | 2007-06-01 | 2021-08-31 | Wyeth Llc | Treatment of imatinib resistant leukemia |
CN101362719B (zh) | 2007-08-06 | 2012-04-18 | 北京师范大学 | 喹啉类衍生物以及包含其的组合物 |
US7939546B2 (en) | 2007-10-12 | 2011-05-10 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
US7790746B2 (en) | 2007-10-12 | 2010-09-07 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
EP2257293A2 (en) | 2008-03-06 | 2010-12-08 | Genentech, Inc. | Combination therapy with c-met and egfr antagonists |
JP2012505904A (ja) | 2008-10-17 | 2012-03-08 | ジェネンテック, インコーポレイテッド | 治療方法 |
DE102008062566A1 (de) * | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
PH12012500097A1 (en) | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
WO2011112588A2 (en) * | 2010-03-08 | 2011-09-15 | Case Western Reserve University | Compositions and methods for treating inflammatory disorders |
EP2552214A4 (en) | 2010-03-26 | 2013-10-16 | Glaxo Group Ltd | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS |
EP2552211A4 (en) | 2010-03-26 | 2013-10-23 | Glaxo Group Ltd | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER |
EP2552208A4 (en) | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS |
ES2552977T3 (es) | 2010-05-07 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolinas como inhibidores de quinasa |
UY33549A (es) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
CA2820709C (en) | 2011-02-28 | 2016-02-16 | Sunshine Lake Pharma Co., Ltd. | Substituted quinoline compounds and methods of use |
AU2012225735B2 (en) | 2011-03-04 | 2016-03-10 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
ES2654100T3 (es) | 2013-02-21 | 2018-02-12 | Glaxosmithkline Intellectual Property Development Limited | Quinazolinas como inhibidores de quinasa |
-
2013
- 2013-09-11 AR ARP130103247A patent/AR092529A1/es unknown
- 2013-09-11 TW TW102132715A patent/TWI592417B/zh not_active IP Right Cessation
- 2013-09-13 CN CN201380047261.2A patent/CN104619327B/zh not_active Expired - Fee Related
- 2013-09-13 PT PT138375712T patent/PT2895174T/pt unknown
- 2013-09-13 NZ NZ628452A patent/NZ628452A/en not_active IP Right Cessation
- 2013-09-13 HU HUE13837571A patent/HUE036347T2/hu unknown
- 2013-09-13 BR BR112015005694A patent/BR112015005694A2/pt active Search and Examination
- 2013-09-13 EP EP13837571.2A patent/EP2895174B1/en active Active
- 2013-09-13 PE PE2015000277A patent/PE20150635A1/es active IP Right Grant
- 2013-09-13 EP EP17209342.9A patent/EP3323819B1/en active Active
- 2013-09-13 DK DK13837571.2T patent/DK2895174T3/en active
- 2013-09-13 US US14/397,218 patent/US9586953B2/en active Active
- 2013-09-13 KR KR1020157006176A patent/KR102101527B1/ko active IP Right Grant
- 2013-09-13 EA EA201590561A patent/EA028146B1/ru not_active IP Right Cessation
- 2013-09-13 WO PCT/US2013/059619 patent/WO2014043446A1/en active Application Filing
- 2013-09-13 ES ES13837571.2T patent/ES2663237T3/es active Active
- 2013-09-13 MX MX2015003276A patent/MX371356B/es active IP Right Grant
- 2013-09-13 AU AU2013315396A patent/AU2013315396B2/en not_active Ceased
- 2013-09-13 JP JP2015532068A patent/JP6246813B2/ja not_active Expired - Fee Related
- 2013-09-13 CA CA2886467A patent/CA2886467C/en not_active Expired - Fee Related
- 2013-09-13 SI SI201330964T patent/SI2895174T1/sl unknown
- 2013-09-13 RS RS20180281A patent/RS57144B1/sr unknown
- 2013-09-13 LT LTEP13837571.2T patent/LT2895174T/lt unknown
- 2013-09-13 PL PL13837571T patent/PL2895174T3/pl unknown
- 2013-09-13 ME MEP-2018-80A patent/ME02985B/me unknown
- 2013-09-13 SG SG11201501139RA patent/SG11201501139RA/en unknown
-
2015
- 2015-02-16 IL IL237263A patent/IL237263B/en active IP Right Grant
- 2015-02-18 PH PH12015500363A patent/PH12015500363A1/en unknown
- 2015-03-12 CL CL2015000614A patent/CL2015000614A1/es unknown
- 2015-03-13 CR CR20150132A patent/CR20150132A/es unknown
- 2015-03-13 DO DO2015000060A patent/DOP2015000060A/es unknown
-
2016
- 2016-01-08 HK HK16100176.8A patent/HK1212223A1/xx not_active IP Right Cessation
- 2016-03-25 US US15/080,969 patent/US9695161B2/en active Active
-
2017
- 2017-05-30 US US15/608,099 patent/US20170258794A1/en not_active Abandoned
-
2018
- 2018-03-08 HR HRP20180411TT patent/HRP20180411T1/hr unknown
- 2018-03-09 CY CY20181100287T patent/CY1120236T1/el unknown
- 2018-08-15 HK HK18110508.4A patent/HK1251222A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2895174T1 (sl) | Predzdravila amino kinazolin kinaznega inhibitorja | |
HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
JP2015529681A5 (sl) | ||
MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
IN2012DN00755A (sl) | ||
MA37405A1 (fr) | Composés hétérocyclyle | |
PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
TN2016000090A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors. | |
TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
EP2288260A4 (en) | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD | |
MX336271B (es) | Compuestos de triazolopiridina inhibidores de jak y los metodos. | |
HK1166788A1 (sl) | ||
WO2017089390A8 (en) | Janus kinases inhibitors, compositions thereof and use thereof | |
MX2010005824A (es) | Derivados de aminotiazol. | |
MD20140124A2 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
WO2006000371A3 (en) | Pyrimidine derivatives as 11beta-hsd1 inhibitors | |
EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
IN2012DN01855A (sl) | ||
WO2011159550A3 (en) | Lysophosphatidic acid receptor antagonist and uses thereof | |
WO2014106800A3 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
MY155922A (en) | Oral administrable pharmaceutical composition | |
WO2010042391A3 (en) | Hiv integrase inhibitors |